Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Anika Therapeutics Inc

ANIK

Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

Last trade $12.75
Day change -$0.17 (-1.32%)
Day range $12.53 – $13.03
Volume 79,287
Market cap $173M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$173.07M
Price / earnings
—
Price / book
1.26×
Price / sales
1.4×
EV / sales
1.04×
EV / EBITDA
41.74×

Profitability

Earnings per share
-$0.13
Return on assets
-0.93%
Return on equity
-1.28%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.86×
Quick ratio
2.72×
Cash ratio
1.68×

Cash flow

Price / cash flow
23.12×
Price / free cash flow
75.41×
Free cash flow
$2.3M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ANIK, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$30.59M$32.61M$29.61M$30.62M$27.82M$28.22M$26.17M$30.6M
Cost of revenue$11.76M$11.37M$10.62M$11.44M$12.23M$13.86M$11.49M$13.48M
Gross profit$18.84M$21.24M$19M$19.18M$15.58M$14.36M$14.68M$17.13M
Selling, general and administrative$11.65M$10.95M$17.77M$12.08M$11.87M$12.23M$12.91M$11.32M
Research and development$7.9M$7.34M$6.71M$6.45M$6.95M$6.31M$6.06M$6.51M
Total operating expenses$19.55M$18.29M$24.49M$18.53M$18.82M$18.54M$18.97M$17.83M
Operating income-$712K$2.95M-$5.49M$646K-$3.23M-$4.18M-$4.28M-$705K
Interest expense$390K$426K$0$0$997K$214K$0$0
Income before taxes-$322K$3.38M-$4.82M$764K-$2.24M-$3.97M-$3.87M$39K
Income taxes-$11K$71K$235K-$1.04M$939K$681K$89K$2.53M
Net income-$311K$3.31M-$5.06M$292K-$2.33M-$3.97M-$4.87M-$21.87M
Net income attributable to common shareholders-$311K$3.31M-$5.06M$292K-$2.33M-$3.97M-$4.87M-$21.87M
EBITDA$727K$4.46M-$4.08M$1.96M-$1.83M-$2.76M-$2.69M$1.11M
Basic earnings per share-$0.02$0.25-$0.37$0.02-$0.16-$0.28-$0.34-$1.50
Diluted earnings per share-$0.02$0.24-$0.37$0.02-$0.16-$0.28-$0.34-$1.50

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates

Anika Therapeutics reported Q3 2026 earnings of $0.29 per share, beating consensus estimates of $0.17 by 70.59%, with revenues of $30.59 million exceeding expectations by 3.94%. The stock has gained 101.1% year-to-date, significantly outperforming the S&P 500's 7.4% gain. However, the company received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies

Novartis announced positive results from late-stage REMODEL-1/-2 studies showing remibrutinib, a BTK inhibitor, significantly reduced annualized relapse rates versus Aubagio in relapsing multiple sclerosis patients. The drug also reduced inflammatory brain lesions with a favorable safety profile. Novartis plans global regulatory filings and will present data at MSToronto2026. Shares gained 6% on the news.

Zacks Investment Research

GSK to Advance mRNA Influenza Vaccine Into Phase III Development

GSK announced it will begin a Phase III efficacy study of its mRNA-based seasonal flu vaccine in September 2026, following positive Phase II results showing higher immune responses than standard and high-dose flu vaccines. The vaccine uniquely targets both HA and NA antigens, unlike most existing flu vaccines. The FDA granted Fast Track designation to the candidate. Moderna's mFlusiva mRNA flu vaccine was recently approved by the FDA for adults 50+.

Zacks Investment Research

Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid

Teva Pharmaceutical has made a bid to acquire certain assets of BioXcel Therapeutics, including Igalmi (dexmedetomidine sublingual film) and the investigational BXCL501 formulation under FDA review for at-home treatment of acute agitation. Teva would pay $57.5 million upfront with up to $67.5 million in contingent payments. The acquisition aligns with Teva's neuroscience expansion strategy and Pivot to Growth initiative.

GlobeNewswire Inc.

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Therapeutics granted 3,360 restricted stock units to a newly hired non-executive employee on June 1, 2026, as part of their employment compensation package. The RSUs will vest in three equal installments over three years, subject to continuous service.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.